In light of this, PADs, in particular PAD2, have been thought to have a detrimental effect in MS, and thus alleviation of symptoms can be achieved by inhibiting their actions (Caprariello et al., 2018). The gene discussed is PADI2; the disease is myeloid sarcoma.